
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 1, 2013

CORONADO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35366
(Commission
File Number)

20-5157386
(IRS Employer
Identification No.)

24 New England Executive Park, Burlington, MA
(Address of Principal Executive Offices)

01803
(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 652-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02. Results of Operations and Financial Condition.

On November 1, 2013, Coronado Biosciences, Inc. issued a press release reporting unaudited financial results for the quarter ended September 30, 2013. A copy of the press release is attached hereto as Exhibit 99.1.

The information in Items 2.02 and 9.01 of this current report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

<u>No.</u>	<u>Description</u>
99.1	Press release dated November 1, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: November 1, 2013

/s/ Dale Ritter

Name: Dale Ritter

Title: Senior Vice President, Finance



Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2013

Burlington, MA – November 1, 2013 – Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the third quarter ended September 30, 2013.

Coronado reported net losses of \$7.8 million and \$27.4 million for the three and nine months ended September 30, 2013, respectively, compared to net losses of \$5.9 million and \$18.9 for the three and nine months ended September 30, 2012, respectively.

Research and development expenses were \$5.4 million and \$19.1 million for the three and nine months ended September 30, 2013, respectively, compared to \$3.8 million and \$12.9 million for the three and nine months ended September 30, 2012, respectively. The increases in research and development expenses relate primarily to increased clinical activities in the TSO development program.

General and administrative expenses totaled \$2.1 million and \$7.1 million for the three and nine months ended September 30, 2013, respectively, compared to \$2.1 million and \$6.0 million for the three and nine months ended September 30, 2012, respectively. The increase in general and administrative expenses for the nine months ended September 30, 2013, compared to the nine months ended September 30, 2012, related primarily to the company's infrastructure growth and increased business activity. At September 30, 2013, Coronado's cash totaled \$106.3 million.

Recent Corporate and Scientific Events:

- Reported top-line results from the TRUST-I phase 2 clinical trial of TSO (*Trichuris suis* ova or CNDO-201) for the treatment of Crohn's disease. The TRUST-I study did not meet its primary endpoint of improving response, defined as a 100-point decrease in the Crohn's Disease Activity Index (CDAI), nor the key secondary endpoint of remission, defined as achieving CDAI < 150 points.
- Initiation of a National Institutes of Health (NIH)-sponsored phase 2 study evaluating TSO for the treatment of ulcerative colitis. This multi-center study is being conducted by the Autoimmunity Centers of Excellence, which are funded through a multi-million dollar grant from the National Institute of Allergy and Infectious Diseases, part of the NIH.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (*Trichuris*

suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, among others, statements we make relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our ability to successfully manufacture TSO in the United States; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; and competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Lucy Lu, MD, Executive Vice President & Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; ir@coronadobio.com

(A development stage enterprise)

Consolidated Balance Sheets

(\$ in thousands)

(Unaudited)

	September 30, 2013	December 31, 2012
ASSETS		
Cash and cash equivalents	\$ 106,267	\$ 40,199
Prepaid and other current assets	279	393
Total current assets	106,546	40,592
Property & equipment net	452	51
Other	109	349
Total Assets	<u>\$ 107,107</u>	<u>\$ 40,992</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities	\$ 9,644	\$ 5,132
Note payable, non-current	8,408	12,386
Other long-term liabilities	1,541	1,441
Total Liabilities	19,593	18,959
Stockholders' Equity	87,514	22,033
Total Liabilities and Stockholders' Equity	<u>\$ 107,107</u>	<u>\$ 40,992</u>

CORONADO BIOSCIENCES, INC. AND SUBSIDIARY

(A development stage enterprise)

Consolidated Statements of Operations

(\$ in thousands except for share amounts)

(Unaudited)

	For the three months ended September 30,		For the nine months ended September 30,	
	2013	2012	2013	2012
Operating expenses:				
Research and development	\$ 5,361	\$ 3,777	\$ 19,130	\$ 12,893
General and administrative	2,143	2,054	7,126	5,984
Loss from operations	(7,504)	(5,831)	(26,256)	(18,877)
Interest income	165	79	350	152
Interest expense	(493)	(183)	(1,454)	(220)
Net loss attributed to Common Stockholders	(\$ 7,832)	(\$ 5,935)	(\$ 27,360)	(\$ 18,945)
Basic and diluted net loss per common share	(\$ 0.24)	(\$ 0.24)	(\$ 0.95)	(\$ 0.91)
Weighted average common shares outstanding—basic and diluted	32,634,683	24,375,749	28,664,822	20,738,007